花旗银行最新研报对医渡科技给予"买入"评级,目标价上调至12港元,认为公司将充分受益于AI技术在医疗行业的广阔应用前景。该行预计,短期内 AI有望通过提高运营效率降低医疗机构员工成本;长远来看,随着 AI 技术日臻成熟,医疗 AI 市场将迎来蓬勃发展期,医渡科技凭借自主研发AI优势和行业积累将充分受益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.